SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
CEO： Mr. Phillip Louis Gomez
Listing Date： 09/09/1997